Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erlotinib vs Chemotherapy as Neoadjuvant Therapy in EGFR-mutant Stage IIIA Lung Adenocarcinoma
NCT02036359Phase 2Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- May 2012
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in lung adenocarcinoma, sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
erlotinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02036359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02036359.